Period:
Draw Mode:
| Volume | 397,276 |
|
|||||
| News | - | ||||||
| Day High | 1.31 | Low High |
|||||
| Day Low | 1.24 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Gossamer Bio Inc | GOSS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.06 | -4.58% | 1.25 | 12:52:08 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.28 | 1.24 | 1.31 | 1.31 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,440 | 397,276 | $ 1.27 | $ 504,856 | - | 0.9103 - 15.195 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:52:08 | 22 | $ 1.2511 | USD |
Gossamer Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 119.31M | 95.44M | 74.25M | $ - | $ - | -0.52 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 925.92k | 5.20% |
Gossamer Bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GOSS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.31 | 1.385 | 1.19 | 1.28 | 1,568,213 | -0.06 | -4.58% |
| 1 Month | 1.36 | 1.62 | 1.09 | 1.34 | 1,933,501 | -0.11 | -8.09% |
| 3 Months | 1.29 | 1.62 | 0.9103 | 1.16 | 2,972,375 | -0.04 | -3.1% |
| 6 Months | 9.00 | 9.55 | 0.9103 | 1.92 | 4,555,897 | -7.75 | -86.11% |
| 1 Year | 7.33 | 15.195 | 0.9103 | 4.08 | 2,985,331 | -6.08 | -82.95% |
| 3 Years | 12.62 | 15.87 | 0.9103 | 5.91 | 1,423,613 | -11.37 | -90.1% |
| 5 Years | 18.72 | 27.1497 | 0.9103 | 7.22 | 1,120,769 | -17.47 | -93.32% |
Gossamer Bio Description
| Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma. |